Skip to main content
. 2016 Feb 4;8(4):305–311. doi: 10.4168/aair.2016.8.4.305

Table 2. Inter-visit difference in group A (montelukast-placebo group).

Phase I P value Phase II P value
Visit 2 (Week 0) Visit 4 (Week 8) Visit 5 (Week 10) Visit 7 (Week 18)
SCORAD index 44.6±18.3 40.7±17.6 0.48 41.7±19.9 34.5±17.4 0.21
U-LTE4 (pg/mL) 585.3±428.1 542.7±429.5 0.74 526.7±412.2 690.2±385.9 0.18
U-EDN (ng/mL) 1,106.7±743.9 883.0±742.2 0.32 1,236.7±749.2 1,016.6±573.3 0.28

SCORAD, SCORing Atopic Dermatitis; U-LTE4, Urine leukotriene E4; U-EDN, Urine eosinophil-derived neurotoxin.